Chromogranin A is not a biomarker of mastocytosis

Hanjra, Pahul; Lee, Chyi‐Chia Richard; Marić, Irina; Carter, Melody; Olivera, Ana; Metcalfe, Dean D.; Komarow, Hirsh D.

doi:10.1016/j.jaip.2017.08.022

Cited by 9 publications

(6 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Diseases such as carcinoid syndrome, pheochromocytoma, gastrinoma, and VIPoma, which could explain many of the symptoms have to be ruled out through specific diagnostic tests. For instance, serum chromogranin A is a biomarker for carcinoid syndrome, but not for SM [154]. If mast cell clonality is absent, mast cell mediators (e.g.…”

Section: Non-clonal Mast Cell Mediator Disordersmentioning

confidence: 99%

Recent advances in our understanding of mast cell activation – or should it be mast cell mediator disorders?

Theoharides

Tsilioni

Ren

2019

Expert Review of Clinical Immunology

View full text Add to dashboard Cite

Introduction: An increasing number of patients present with multiple symptoms affecting many organs including the brain due to multiple mediators released by mast cells. These unique tissue immune cells are critical for allergic reactions triggered by immunoglobulin E (IgE), but are also stimulated (not activated) by immune, drug, environmental, food, infectious, and stress triggers, leading to secretion of multiple mediators often without histamine and tryptase. The presentation, diagnosis, and management of the spectrum of mast cell disorders are very confusing. As a result, specialists have recently excluded neuropsychiatric symptoms, and made the diagnostic criteria stricter, at the expense of excluding most patients.

show abstract

Section: Non-clonal Mast Cell Mediator Disordersmentioning

confidence: 99%

Recent advances in our understanding of mast cell activation – or should it be mast cell mediator disorders?

Theoharides

Tsilioni

Ren

2019

Expert Review of Clinical Immunology

View full text Add to dashboard Cite

show abstract

“…Moreover, the use of proton pump inhibitors may be associated with elevated serum CgA in patients with mastocytosis; however, this finding does not correlate with MC burden or activation. 75 Thus, CgA levels are not elevated in patients with mastocytosis. 75…”

Section: Laboratory Criterionmentioning

confidence: 96%

“…6,47,51,52,58,66,[68][69][70] Other potential markers that have been discussed in the context of MCA include heparin, serotonin, neuropeptides, platelet-activating factor, and chromogranin A (CgA). 13,[71][72][73][74][75][76] However, there are insufficient data to demonstrate their clinical utility in the diagnosis of MCA and MCAS. For instance, serum levels of CgA have been reported to be fairly specific to MCs; however, there is no study providing evidence that human MCs are a relevant source for CgA.…”

Section: Laboratory Criterionmentioning

confidence: 99%

Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review

Gülen

Akin

Bonadonna

et al. 2021

The Journal of Allergy and Clinical Immunology: In Practice

Self Cite

View full text Add to dashboard Cite

“…Moreover, the clinical utility of serotonin, neuropeptides, heparin, platelet-activating factor (PAF), and chromogranin A (CgA) as potential biomarkers for MC activation remains unproven due to insufficient data, despite ongoing discussions [ 51 – 57 ]. For instance, the reported rise in plasma heparin activity following venous occlusion in patients with MC activation symptoms does not serve as sufficient validation for utilizing this test as a biomarker for MC activation [ 54 ].…”

Section: Mast Cell Activation Syndromementioning

confidence: 99%

Using the Right Criteria for MCAS

Gulen

2024

Curr Allergy Asthma Rep

View full text Add to dashboard Cite

Purpose of Review The current article aims to provide a comprehensive update on diagnostic criteria for mast cell activation syndrome (MCAS), addressing challenges in diagnosing and classifying MCAS and its variants. Recent Findings In recent years, there has been a significant increase in our knowledge regarding the underlying mechanisms responsible for the activation of mast cells (MCs) in various pathological conditions. Furthermore, a set of criteria and a classification for MCASs have been established. MCAS is characterized by the presence of typical clinical symptoms, a substantial elevation in serum tryptase levels during an attack compared to the patient’s baseline tryptase levels, and a response to MC mediator–targeting therapy. Summary In this report, a thorough examination was conducted on the contemporary literature relating to MCAS, with a focus on comparing the specificity, sensitivity, and robustness of MCAS-related parameters within proposals for diagnosing and classifying MCAS and its variants. Moreover, the significance of employing specific consensus criteria in the assessment and categorization of MCAS in individual patients was underscored, due to the escalating occurrence of patients receiving a misdiagnosis of MCAS based on nonspecific criteria.

show abstract

Chromogranin A is not a biomarker of mastocytosis

Cited by 9 publications

References 13 publications

Recent advances in our understanding of mast cell activation – or should it be mast cell mediator disorders?

Recent advances in our understanding of mast cell activation – or should it be mast cell mediator disorders?

Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review

Using the Right Criteria for MCAS

Contact Info

Product

Resources

About